400-901-9800
sales@bioss.com.cn
support@bioss.com.cn
www.bioss.com.cn

Product Details

Product name:	**Anti-CTLA4 & PD-L1 (Erfonrilimab Biosimilar)**	**SKU:**	**BIO0963SM**
Target Name:	**CTLA4 & PD-L1**	**Size:**	**100ug/ 1mg/ 5mg**
Target Uniprot:	**P16410 & Q9NZQ7**	**Concentration:**	**Lyophilized**
Clone#:	**Erfonrilimab (Bispecific)**	**Isotype:**	**VHH-VHH-Fc**
Reactivity:	**Human**	**Calculated M.W.:**	**107.44 kDa**
Application:	**ELISA, Bioactivity: FACS, Functional assay, Research in vivo**	**Endotoxin:**	**<0.001 EU/ug**
Formulation:	**100 mM Pro-Ac 20mM Arg pH 5.0**	**Conjugation:**	**None**
Storage:	**-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.**	**Expression System:**	**CHO**
Reconstitution:	**Dissolve with sterile ddH₂O**	**Purification:**	**Protein A**

Data

Purity: SDS-PAGE



Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC



The purity of Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) is 97.11%, determined by SEC-HPLC.

ELISA



Erfonrilimab bound to CTLA4 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Erfonrilimab bound in human CTLA4 Protein-His, and the EC50 was 0.010 nM.

ELISA



Erfonrilimab bound to PD-L1 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Erfonrilimab bound in human PD-L1 Protein-His, and the EC50 was 0.012 nM.

Bioactivity: FACS



Erfonrilimab bound to huCTLA4-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Erfonrilimab bound to huCTLA4-CHO-K cells, and the EC50 was 14.510 nM.

Bioactivity: FACS



Erfonrilimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Erfonrilimab bound to huPD-L1-CHO-K cells, and the EC50 was 1.759 nM.

Function: Luciferase



Co-incubation of Erfonrilimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Erfonrilimab was able to block the PD-1/PD-L1 signaling pathway,and the EC50 was 0.681 nM.